Health Insider

Drug Pricing In Spotlight: March-In Comments Due, CBO To Release Updated IRA Score

By Amy Lotven, Bridget Early, Dorothy Mills-Gregg / February 5, 2024 at 9:10 PM
It’s a big week for drug pricing policy: Tuesday (Feb. 6) is the deadline for stakeholders to submit feedback on the administration’s proposal to change long-standing policy and use high drug prices as a reason to step-in and seize patents under its march-in rights. While drug pricing advocates had pushed for the change, the initial framework out Dec. 7 was criticized by some stakeholders who worry that the administration’s proposal to require “extreme” prices to would render the policy useless;...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.